A Phase 4 interventional study of JZP258 (XYWAV) in Idiopathic Hypersomnia and Narcolepsy, sponsored by Jazz Pharmaceuticals. Completed at 32 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-27.
Sponsored by Jazz Pharmaceuticals · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Idiopathic Hypersomnia with a site in United States — 12 open to participants now, 13 under way, 4 of them phase 3. Idiopathic Hypersomnia · United States.
Among the 30 studies in Idiopathic Hypersomnia with a site in United States, this one is the 6th largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2023, is one of 2 in phase 4, and was the 18th registered.
53 studies on the registry are indexed under Idiopathic Hypersomnia; 24 are open to participants now.
Browse Idiopathic Hypersomnia studies →12 of the 30 studies in Idiopathic Hypersomnia with a site in United States are open now. Recruiting first, the newest first:
Jazz Pharmaceuticals · Sites in United States
Ages 18–75
Takeda · Sites in United States, Australia, China and 2 more countries
Ages 18–71
University of Pittsburgh · Sites in United States
Ages 18+ · Healthy volunteers
Harmony Biosciences Management, Inc. · Sites in United States, Canada
Ages 18+
Centessa Pharmaceuticals (UK) Limited · Sites in United States, Canada, Italy and 1 more country
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Idiopathic Hypersomnia studies recruiting now, 4 (24%) set no upper age limit and 12 (71%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 13 · Phase 3 8 · Phase 4 2
First in 2010; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 199 is above the median of 82 across 40 interventional studies indexed under Idiopathic Hypersomnia.
Median enrollment 100 across the 27 interventional studies, 100 across the 3 observational. Of the 16 that completed or were terminated, 10 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 30 have an industry lead sponsor. The 10 most frequent:
Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
Jazz Pharmaceuticals has 3 studies filed under Idiopathic Hypersomnia — fewer than ten, so there is no comparison to draw.
5 of the studies in Idiopathic Hypersomnia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07500090Phase 3Harmony Biosciences Management, Inc.A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH) | 2027-10 |
| NCT06843590Alkermes, Inc.A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia | 2026-11 |
| NCT06812078TakedaA Study of TAK-360 in Adults With Idiopathic Hypersomnia | 2026-11-30 |
| NCT06752668Centessa Pharmaceuticals (UK) LimitedA Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia | 2026-12 |
| NCT05837091Mayo ClinicLow Sodium Oxybate in Patients With Idiopathic Hypersomnia | 2027-01-29 |
Add all 5 to your calendar (.ics) → With an account.
Among the 30 studies in Idiopathic Hypersomnia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess the safety and efficacy of JZP258 (XYWAV) on sleepiness, polysomnography, and functional outcomes in patients with idiopathic hypersomnia (IH) or narcolepsy.
This prospective, multicenter, single-arm, open-label interventional study will assess the safety and efficacy of JZP258 on sleepiness, polysomnography measurements (eg, sleep stage transitions, sleep patterns, and sleep quality), daytime and nighttime symptoms, pharmacokinetics (in narcolepsy), and patient-reported outcomes that include subjective sleep quality and quality of life in patients with IH or narcolepsy.
Key Inclusion Criteria:
Additional Inclusion Criteria for Participants in the Exploratory Narcolepsy >9-Gram Cohort
Key Exclusion Criteria:
Has recently taken (ie, within 1 month prior to screening), is taking, or plans to take any of the following:
Additional Exclusion Criterion for Participants in the Exploratory Narcolepsy >9-Gram Cohort
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will self-administer an oral dose of JZP258 (XYWAV) as per label and titrate to an optimal dosage for each participant.
Drug: JZP258 (XYWAV)
Narcolepsy Cohort: Initiate dosage per XYWAV label and titrate to effect. IH Cohort: Initiate dosage per XYWAV label and titrate to effect. Exploratory Narcolepsy \>9-Gram Cohort: XYWAV titrated to a dosage of \>9 to 12 grams.
Change From Baseline in Epworth Sleepiness Scale (ESS) Total Score in Participants With IH and Narcolepsy Treated With XYWAV
The ESS total score (the sum of 8 item scores, each 0 to 3) can range from 0 to 24. Higher ESS total scores are associated with higher sleep propensity in daily life, also referred to as "daytime sleepiness."
Time frame: Baseline up to End of Treatment (approximately 10-36 weeks)
Change From Baseline in Idiopathic Hypersomnia Severity Scale (IHSS) Total Score in Participants With IH Treated With XYWAV
The IHSS is a 14-item self-reported instrument that assesses the severity and functional consequences of IH symptoms. Questions capture symptoms of excessive sleepiness, sleep inertia, and long sleep duration. IHSS total scores range from 0 to 50 with higher score indicating worse clinical outcome.
Time frame: Baseline up to End of Treatment (approximately 10-21 weeks)
Change From Baseline in Number of Stage Shifts of Sleep in Participants With Narcolepsy Treated With XYWAV
Stage shifts of sleep are defined as the count of transitions of bouts of sleep from deeper to lighter stages of sleep/wake (ie from N3/N2/N1/REM to wake and from N3/N2/REM to N1).
Time frame: Baseline up to End of Treatment (approximately 10-36 weeks)
Change From Baseline in Duration of Sleep Stages in Participants With Narcolepsy Treated With XYWAV
Duration of sleep stages is measured in minutes (ie N1/N2/N3/REM) and is recorded from sleep onset to awakening during the nocturnal polysomnograph.
Time frame: Baseline up to End of Treatment (approximately 10-36 weeks)
Change From Baseline in Number of Nocturnal Awakenings and Nocturnal Arousals in Participants With Narcolepsy Treated With XYWAV
Time frame: Baseline up to End of Treatment (approximately 10-36 weeks)
Change From Baseline in Percentage of Sleep Stages in Participants With Narcolepsy Treated With XYWAV
The percentage of sleep stages is measured as minutes of each sleep stage (N3/N2/N1/REM) per hour of sleep time from sleep onset to awakening in the nocturnal polysomnograph.
Time frame: Baseline up to End of Treatment (approximately 10-36 weeks)
Patient Global Impression of Change (PGI-C) in Participants With IH and Narcolepsy Treated With XYWAV (Overall, Sleep Inertia, and Fatigue)
The PGI-C is a single-item 7-point, Likert-type scale for rating change in disease or symptom severity. Responses for each question ranged from 1 (very much improved) to 7 (very much worse) relative to baseline. Participants rated the change from baseline in their overall (IH or narcolepsy) symptoms, sleep inertia (difficulty waking in the morning), and fatigue (extreme tiredness resulting from mental or physical exertion).
Time frame: End of Treatment (approximately 10-36 weeks)
Level of Rested or Refreshed Upon Awakening in Participants With IH and Narcolepsy Treated With XYWAV (Sleep Diary)
The participant was asked "How rested or refreshed did you feel when you woke up for the day?"
Time frame: Baseline up to End of Treatment (approximately 10-36 weeks)
Patient Global Impression of Severity (PGI-S) Score in Participants With IH and Narcolepsy Treated With XYWAV (Overall, Sleep Inertia, and Fatigue)
The PGI-S is a single-item, 7-point, Likert-type scale for rating disease or symptom severity. Responses ranged from 0 (not present) to 7 (extremely severe). Participants rated the severity of their overall (IH or narcolepsy) symptoms, sleep inertia, and fatigue. Higher scores indicate worse clinical outcome.
Time frame: Baseline up to End of Treatment (approximately 10-36 weeks)
Pharmacokinetic Parameter Maximum Plasma Concentration (Cmax) In a Subset of Participants With Narcolepsy Treated With XYWAV
Blood samples were processed to obtain plasma samples and then analyzed for oxybate concentrations using a validated bioanalytical method.
Time frame: PK: Predose, 0.5 hour, 0.75 hour, 1 hour, 1.5 hour post-first dose and post-second dose, 6 hour post-first dose, 8 hour post-first dose
Pharmacokinetic Parameter Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) In a Subset of Participants With Narcolepsy Treated With XYWAV
Blood samples were processed to obtain plasma samples and then analyzed for oxybate concentrations using a validated bioanalytical method.
Time frame: PK: Predose, 0.5 hour, 0.75 hour, 1 hour, 1.5 hour post-first dose and post-second dose, 6 hour post-first dose, 8 hour post-first dose
The Enrolled Analysis Set included n=66 Idiopathic Hypersomnia; n=68 Narcolepsy; n=65 \> 9-g Narcolepsy. Each cohort has a cohort-specific ICF and a unique set of protocol specified assessments/procedures. Participants in the \>9-g Narcolepsy cohort were either already taking 9 g/night of Xywav at screening or had titrated to 9 g of Xywav while in the Narcolepsy cohort, discontinued from this cohort, and signed a new ICF to begin the \>9-g Narcolepsy cohort (referred to as "transfer participants").
| Milestone | Idiopathic Hypersomnia (IH) | Narcolepsy | Exploratory > 9-g Narcolepsy |
|---|---|---|---|
| Started | 66 | 68 | 65 |
| Completed | 46 | 55 | 51 |
| Not completed | 20 | 13 | 14 |
| Withdrew: Screen failures | 20 | 13 | 14 |
| Milestone | Idiopathic Hypersomnia (IH) | Narcolepsy | Exploratory > 9-g Narcolepsy |
|---|---|---|---|
| Started | 46 | 55 | 48 |
| Transferred from narcolepsy cohort and received >9g treatment | 0 | 0 | 11 |
| Completed | 40 | 34 | 44 |
| Not completed | 6 | 21 | 4 |
| Withdrew: Adverse event | 1 | 2 | 2 |
| Withdrew: Physician decision | 2 | 0 | 0 |
| Withdrew: Protocol deviation | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 3 | 1 |
| Withdrew: Pregnancy | 0 | 1 | 0 |
| Withdrew: Sponsor request | 0 | 1 | 0 |
| Withdrew: Noncompliance with study schedule | 0 | 0 | 1 |
| Withdrew: Transferred to > 9-g narcolepsy cohort | 0 | 13 | 0 |
The ESS total score (the sum of 8 item scores, each 0 to 3) can range from 0 to 24. Higher ESS total scores are associated with higher sleep propensity in daily life, also referred to as "daytime sleepiness."
| score on a scale | Idiopathic Hypersomnia (IH) | Narcolepsy |
|---|---|---|
| Change From Baseline in Epworth Sleepiness Scale (ESS) Total Score in Participants With IH and Narcolepsy Treated With XYWAV | -8.38 ± 0.695 | -7.68 ± 0.931 |
The IHSS is a 14-item self-reported instrument that assesses the severity and functional consequences of IH symptoms. Questions capture symptoms of excessive sleepiness, sleep inertia, and long sleep duration. IHSS total scores range from 0 to 50 with higher score indicating worse clinical outcome.
| score on a scale | Idiopathic Hypersomnia (IH) |
|---|---|
| Change From Baseline in Idiopathic Hypersomnia Severity Scale (IHSS) Total Score in Participants With IH Treated With XYWAV | -15.53 ± 1.490 |
Stage shifts of sleep are defined as the count of transitions of bouts of sleep from deeper to lighter stages of sleep/wake (ie from N3/N2/N1/REM to wake and from N3/N2/REM to N1).
| stage shifts | Narcolepsy |
|---|---|
| Change From Baseline in Number of Stage Shifts of Sleep in Participants With Narcolepsy Treated With XYWAV | -13.06 ± 2.908 |
Duration of sleep stages is measured in minutes (ie N1/N2/N3/REM) and is recorded from sleep onset to awakening during the nocturnal polysomnograph.
| minutes | Narcolepsy |
|---|---|
| Stage N1 Sleep Duration: Full Night, Visit 4 (End of Treatment) | -8.12 ± 3.303 |
| Stage N2 Sleep Duration: Full Night, Visit 4 (End of Treatment) | 1.5 ± 12.343 |
| Stage N3 Sleep Duration: Full Night, Visit 4 (End of Treatment) | 45.01 ± 8.822 |
| Stage REM Sleep Duration: Full Night, Visit 4 (End of Treatment) | -39.18 ± 5.716 |
| awakenings/arousals | Narcolepsy |
|---|---|
| Number of awakenings: Full Night, Visit 4 (End of Treatment) | -3.18 ± 0.903 |
| Total number of all arousals: Full Night, Visit 4 (End of Treatment | -23.88 ± 7.564 |
The percentage of sleep stages is measured as minutes of each sleep stage (N3/N2/N1/REM) per hour of sleep time from sleep onset to awakening in the nocturnal polysomnograph.
| percentage of sleep stages | Narcolepsy |
|---|---|
| Stage N1 Sleep/Total Sleep Time: Full Night, Visit 4 (End of Treatment) | -2.18 ± 0.696 |
| Stage N2 Sleep/Total Sleep Time: Full Night, Visit 4 (End of Treatment) | 0.03 ± 1.923 |
| Stage N3 Sleep/Total Sleep Time: Full Night, Visit 4 (End of Treatment) | 10.28 ± 1.890 |
| Stage REM Sleep/Total Sleep Time: Full Night, Visit 4 (End of Treatment) | -8.13 ± 1.242 |
The PGI-C is a single-item 7-point, Likert-type scale for rating change in disease or symptom severity. Responses for each question ranged from 1 (very much improved) to 7 (very much worse) relative to baseline. Participants rated the change from baseline in their overall (IH or narcolepsy) symptoms, sleep inertia (difficulty waking in the morning), and fatigue (extreme tiredness resulting from mental or physical exertion).
| Participants | Idiopathic Hypersomnia (IH) | Narcolepsy |
|---|---|---|
| Very much improved | 8 | 4 |
| Much improved | 18 | 19 |
| Minimally improved | 9 | 5 |
| No change | 1 | 2 |
| Minimally worse | 1 | 0 |
| Much worse | 0 | 0 |
| Very much worse | 0 | 0 |
The participant was asked "How rested or refreshed did you feel when you woke up for the day?"
| Participants | Idiopathic Hypersomnia (IH) | Narcolepsy |
|---|---|---|
| Baseline, Sleep Quality Very poor | 4 | 3 |
| Baseline, Sleep Quality Poor | 12 | 14 |
| Baseline, Sleep Quality Fair | 13 | 10 |
| Baseline, Sleep Quality Good | 7 | 5 |
| Baseline, Sleep Quality Very Good | 0 | 0 |
| Visit 4 End of Treatment, Sleep Quality Very poor | 0 | 0 |
| Visit 4 End of Treatment, Sleep Quality Poor | 2 | 0 |
| Visit 4 End of Treatment, Sleep Quality Fair | 11 | 6 |
| Visit 4 End of Treatment, Sleep Quality Good | 12 | 11 |
| Visit 4 End of Treatment, Sleep Quality Very Good | 5 | 3 |
| Baseline, Not at all rested | 11 | 4 |
| Baseline, Slightly rested | 17 | 13 |
| Baseline, Somewhat rested | 6 | 11 |
| Baseline, Well rested | 2 | 4 |
| Baseline, Very well rested | 0 | 0 |
| Visit 4 End of Treatment, Not at all rested | 6 | 0 |
| Visit 4 End of Treatment, Slightly rested | 2 | 2 |
| Visit 4 End of Treatment, Somewhat rested | 12 | 7 |
| Visit 4 End of Treatment, Well rested | 8 | 9 |
| Visit 4 End of Treatment, Very well rested | 2 | 2 |
The PGI-S is a single-item, 7-point, Likert-type scale for rating disease or symptom severity. Responses ranged from 0 (not present) to 7 (extremely severe). Participants rated the severity of their overall (IH or narcolepsy) symptoms, sleep inertia, and fatigue. Higher scores indicate worse clinical outcome.
| score on a scale | Idiopathic Hypersomnia (IH) | Narcolepsy |
|---|---|---|
| Baseline | 5.3 ± 0.92 | 5.4 ± 1.07 |
| Visit 4, End of Treatment | 3.8 ± 1.33 | 3.6 ± 1.40 |
Blood samples were processed to obtain plasma samples and then analyzed for oxybate concentrations using a validated bioanalytical method.
| ug/mL | Narcolepsy |
|---|---|
| Pharmacokinetic Parameter Maximum Plasma Concentration (Cmax) In a Subset of Participants With Narcolepsy Treated With XYWAV | 107.61 ± 1.534 |
Blood samples were processed to obtain plasma samples and then analyzed for oxybate concentrations using a validated bioanalytical method.
| h*µg/mL | Narcolepsy |
|---|---|
| Pharmacokinetic Parameter Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) In a Subset of Participants With Narcolepsy Treated With XYWAV | 474.00 ± NA |
Collected over Adverse events were collected from Screening up to Safety Follow Up visit, approximately 14 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Idiopathic Hypersomnia (IH) | 0/46 (0%) | 1/46 (2.2%) | 34/46 (73.9%) |
| Narcolepsy | 0/55 (0%) | 0/55 (0%) | 34/55 (61.8%) |
| > 9-g Narcolepsy | 0/48 (0%) | 1/48 (2.1%) | 36/48 (75%) |
| Event | Idiopathic Hypersomnia (IH) | Narcolepsy | > 9-g Narcolepsy |
|---|---|---|---|
| HypoxiaRespiratory, thoracic and mediastinal disorders | 1/46 | 0/55 | 0/48 |
| SyncopeNervous system disorders | 0/46 | 0/55 | 1/48 |
| Event | Idiopathic Hypersomnia (IH) | Narcolepsy | > 9-g Narcolepsy |
|---|---|---|---|
| NauseaGastrointestinal disorders | 9/46 | 13/55 | 6/48 |
| DizzinessNervous system disorders | 8/46 | 8/55 | 0/48 |
| HeadacheNervous system disorders | 8/46 | 7/55 | 5/48 |
| VomitingGastrointestinal disorders | 5/46 | 6/55 | 6/48 |
| SomnolenceNervous system disorders | 3/46 | 6/55 | 4/48 |
| Middle insomniaPsychiatric disorders | 4/46 | 2/55 | 0/48 |
| EnuresisPsychiatric disorders | 3/46 | 3/55 | 4/48 |
| AnxietyPsychiatric disorders | 3/46 | 4/55 | 2/48 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 2/46 | 4/55 | 2/48 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/46 | 4/55 | 1/48 |
Baseline and demographic characteristics were assessed in the Safety Analysis Set.
| Age, Continuous(years) | Idiopathic Hypersomnia (IH) | Narcolepsy | Exploratory > 9-g Narcolepsy | Total |
|---|---|---|---|---|
| IH and Narcolepsy cohorts | 38.1 ± 11.77 | 33.4 ± 12.87 | — | 35.6 ± 12.5 |
| Exploratory >9-g Narcolepsy cohort | — | — | 39.2 ± 10.92 | 39.2 ± 10.92 |
| Sex/Gender, Customized(Participants) | Idiopathic Hypersomnia (IH) | Narcolepsy | Exploratory > 9-g Narcolepsy | Total |
|---|---|---|---|---|
| IH and Narcolepsy cohorts — Male (at birth) | 9 | 15 | — | 24 |
| IH and Narcolepsy cohorts — Female (at birth) | 37 | 40 | — | 77 |
| Exploratory >9-g Narcolepsy cohort — Male (at birth) | — | — | 18 | 18 |
| Exploratory >9-g Narcolepsy cohort — Female (at birth) | — | — | 30 | 30 |
| Race/Ethnicity, Customized(Participants) | Idiopathic Hypersomnia (IH) | Narcolepsy | Exploratory > 9-g Narcolepsy | Total |
|---|---|---|---|---|
| IH and Narcolepsy cohorts — Asian | 2 | 2 | — | 4 |
| IH and Narcolepsy cohorts — Black or African American | 3 | 7 | — | 10 |
| IH and Narcolepsy cohorts — Native Hawaiian or Other Pacific Islander | 1 | 0 | — | 1 |
| IH and Narcolepsy cohorts — White | 39 | 44 | — | 83 |
| IH and Narcolepsy cohorts — Multiple | 1 | 1 | — | 2 |
| IH and Narcolepsy cohorts — Unknown | 0 | 1 | — | 1 |
| Exploratory >9-g Narcolepsy cohort — Asian | — | — | 1 | 1 |
| Exploratory >9-g Narcolepsy cohort — Black or African American | — | — | 7 | 7 |
| Exploratory >9-g Narcolepsy cohort — Native Hawaiian or Other Pacific Islander | — | — | 0 | 0 |
| Exploratory >9-g Narcolepsy cohort — White | — | — | 37 | 37 |
| Exploratory >9-g Narcolepsy cohort — Multiple | — | — | 1 | 1 |
| Exploratory >9-g Narcolepsy cohort — Unknown | — | — | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2023 to primary completion in Mar 2025, 19 months.
Results were first posted in Aug 2026, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: JZP258